Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
New CEO commentary: “The Single-Cell Revolution”
PHI’s CEO and founder Peter Egelberg comments the recently published innovation report from the UN agency World Intellectual Property Organization.
Interim Report 2 2019/20
Interim Report 2 (2019-05-01 – 2019-10-31) from Phase Holographic Imaging.
Label your Tubes, Not your Cells
In this PHI webinar, Lisa Bodily, Application Specialist at PHI AB, introduces the exciting field of label-free live cell imaging.
HoloMonitor saves your time, money – and cells
HoloMonitor® enables real-time label-free and quantitative studies of adherent cells directly in the cell incubator. Compared to standard methods the HoloMonitor approach saves both time, money and valuable cells for further experiments.
Growing & Analyzing Cells at their Best
BioSpherix and Phase Holographic Imaging (PHI) have teamed up to support researchers in their ambition to grow and analyze cells in a cell-friendly environment, without cell disturbing factors like labels, stains and temperature fluctuations.
Quantitative Live-Cell Imaging Analysis
Since 2014, HoloMonitor and quantitative live-cell imaging analysis play an important role in advancing the scientific interests of researchers at Northeastern University.
New SelectScience eBook helps scientists choose the best cell imaging technology
A new cell imaging technology guide has been launched by leading independent science publisher SelectScience® to help scientists find the best equipment for their applications.
Interim Report 1 2019/20
Interim Report 1 (2019-05-01 – 2019-07-31) from Phase Holographic Imaging.
US National Institutes of Health intends to purchase HoloMonitor
The US National Institute of Aging intends to purchase a HoloMonitor instrument from Phase Holographic Imaging. The National Institute of Aging is part of the National Institutes of Health (NIH), a government agency to promote medical research.
Minor insider divestment
PHI Board member Jan Richardsson recently divested 5 328 shares in the company. “The reason for the sale is that I needed to balance an option loss linked to a previous employment”, comments Richardsson.